Materias dentro de su búsqueda.
Mostrando 2,481 - 2,500 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.59s Limitar resultados
  1. 2481
    “…Human epidermal growth factor receptor-2 (HER2) is responsible for 20% of all BC cases. The use of anti-HER2 natural compounds in the cure of BC that is HER2-positive patients has resulted in significant increases in survival in both early and advanced stages. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Screening, Docking, and Molecular Dynamics Study of Natural Compounds as an Anti-HER2 for the Management of Breast Cancer
  2. 2482
    “…PIK3CA mutations are also present in triple negative BC (TNBC) and HER2+ BC, although the role of PI3K inhibition is not well established in these subtypes. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
  3. 2483
    “…This case presents a 66-year-old female, who had mastectomy surgery followed by adjuvant chemo- and radiotherapy for an ER-negative, HER2-positive breast cancer on her right side in 2003, and a mastectomy followed by endocrine therapy for an ER-positive, HER2 normal breast cancer on her left side in 2006. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Calcium Electroporation for Management of Cutaneous Metastases in HER2-Positive Breast Cancer: A Case Report
  4. 2484
    “…Human epidermal growth factor receptor type 2 (HER2) is overexpressed in various cancers; thus, HER2-targeting single-domain antibodies (sdAb) could offer a useful platform for radioimmunotherapy. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Preclinical Evaluation of (225)Ac-Labeled Single-Domain Antibody for the Treatment of HER2(pos) Cancer
  5. 2485
    “…Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report
  6. 2486
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    “It Almost Makes Her Human”: How Female Animal Guardians Construct Experiences of Cat and Dog Empathy
  7. 2487
    “…While senescence-inducing drugs did not increase the cytotoxic effect of ADCs on target cells, the bystander effect was enhanced when HER2-negative cells were cocultured with HER2-low cells. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer
  8. 2488
    por Pachana, Nancy A.
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A passion for aging in cultural contexts: Dr. Colette Browning and her contributions within Australia and globally
  9. 2489
    “…(1) Objective: To evaluate the performance of ultrasound-based radiomics in the preoperative prediction of human epidermal growth factor receptor 2-positive (HER2+) and HER2− breast carcinoma. (2) Methods: Ultrasound images from 309 patients (86 HER2+ cases and 223 HER2− cases) were retrospectively analyzed, of which 216 patients belonged to the training set and 93 patients assigned to the time-independent validation set. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Development and Validation of an Ultrasound-Based Radiomics Nomogram for Identifying HER2 Status in Patients with Breast Carcinoma
  10. 2490
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expression of Concern: The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies
  11. 2491
    por Zhang, Shirong, Wang, Wenxian, Xu, Chunwei, Zhang, Yongchang, Cai, Xiuyu, Wang, Qian, Song, Zhengbo, Li, Ziming, Yu, Jinpu, Zhong, Wenzhao, Wang, Zhijie, Liu, Jingjing, Liu, Anwen, Li, Wen, Zhan, Ping, Liu, Hongbing, Lv, Tangfeng, Miao, Liyun, Min, Lingfeng, Lin, Gen, Huang, Long, Yuan, Jingping, Jiang, Zhansheng, Pu, Xingxiang, Rao, Chuangzhou, Lv, Dongqing, Yu, Zongyang, Li, Xiaoyan, Tang, Chuanhao, Zhou, Chengzhi, Zhang, Junping, Guo, Hui, Chu, Qian, Meng, Rui, Liu, Xuewen, Wu, Jingxun, Zhou, Jin, Zhu, Zhengfei, Pan, Weiwei, Dong, Xiaowei, Pang, Fei, Wang, Kai, Yao, Chao, Lin, Guomin, Li, Site, Yang, Zhi, Luo, Jiancheng, Jia, Hongtao, Nie, Xiuqing, Wang, Liping, Zhu, Youcai, Hu, Xiao, Xie, Yanru, Lin, Xinqing, Cai, Jing, Xia, Yang, Feng, Huijing, Wang, Lin, Du, Yingying, Yao, Wang, Shi, Xuefei, Niu, Xiaomin, Yuan, Dongmei, Yao, Yanwen, Kang, Jing, Zhang, Jiatao, Zhang, Chao, Gao, Wenbin, Huang, Jianhui, Zhang, Yinbin, Sun, Pingli, Wang, Hong, Ye, Mingxiang, Wang, Dong, Wang, Zhaofeng, Wan, Bing, Lv, Donglai, Yu, Genhua, Shi, Lin, Xia, Yuanli, Gao, Feng, Zhang, Xiaochen, Xu, Tao, Zhou, Wei, Wang, Haixia, Liu, Zhefeng, Yang, Nong, Wu, Lin, Wang, Qiming, Wang, Guansong, Hong, Zhuan, Wang, Jiandong, Fang, Meiyu, Fang, Yong, Zhang, Yiping, Song, Yong, Ma, Shenglin, Fang, Wenfeng, Lu, Yuanzhi
    Publicado 2022
    “…Human epidermal growth factor receptor 2 (HER2) possesses tyrosine kinase activity and participates in cell growth, differentiation and migration, and survival. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Chinese expert consensus on the diagnosis and treatment of HER2‐altered non–small cell lung cancer
  12. 2492
    por Lin, N.U.
    Publicado 2022
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Expanding the role of systemic therapy for patients with active, HER2-positive breast cancer brain metastases
  13. 2493
    “…The immunohistochemical (IHC) evaluation of epidermal growth factor 2 (HER2) for the diagnosis of breast cancer is still qualitative with a high degree of inter-observer variability, and thus requires the incorporation of complementary techniques such as fluorescent in situ hybridization (FISH) to resolve the diagnosis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry
  14. 2494
    “…Our study provided evidence that the usage of dalpiciclib in the treatment of HER2(+)/HR(+) breast cancer could partially abrogate the estrogen signaling pathway activation caused by anti-HER2 therapy and revealed that CALML5 could serve as a risk factor in the treatment of HER2(+)/HR(+) breast cancer.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2(+)HR(+) breast cancer
  15. 2495
    por Deng, Lan, Zhao, Le, Liu, Lifen, Huang, Haomin
    Publicado 2023
    “…Although the combination of trastuzumab with pertuzumab produced synergetic effects in the treatment of HER2-overexpressing cancers, not all patients with HER2 overexpression benefited from the trastuzumab plus pertuzumab combination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
  16. 2496
    “…BACKGROUND: Due to radioresistance, some HER2+ patients may gain limited benefit from radiotherapy (RT) after breast-conserving surgery (BCS). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The role of radiotherapy in HER2+ early-stage breast cancer patients after breast-conserving surgery
  17. 2497
    “…BACKGROUND: Novel antibody‒drug conjugates (ADC) have shown great efficacy in HER2-low advanced breast cancer. However, the clinical features of HER2-low disease still need to be clarified. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression
  18. 2498
    “…SIMPLE SUMMARY: Tucatinib is recommended by different guidelines as a third line of treatment in HER2(+) breast cancer. Although it is an effective treatment, different studies have highlighted that the high price of the drug makes it a not cost-effective treatment option. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
  19. 2499
    “…SIMPLE SUMMARY: Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC) represents a subgroup of breast cancer characterized by an aggressive behaviour and a particular sensitiveness to HER2-targeted agents. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
  20. 2500
    “…Bladder cancer (BC) is a heterogeneous disease from a molecular, morphological, and clinical standpoint. HER2 is a known oncogene involved in bladder carcinogenesis. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role
Herramientas de búsqueda: RSS